In children, the optimal mobilization schedule for harvesting peripheral blood progenitor cells (PBPC) is an issue of continuous research. We have studied a schedule based on high and daily divided doses of G-CSF (12 g/kg body weight twice daily) for 4 days for PBPC priming. Toxicity related to G-CSF was observed in 13 patients (23%), mainly mild bone pain and myalgia. In children, peripheral blood progenitor cells (PBPC) are progressively substituting bone marrow as a source of stem cells for hematopoietic transplantation due to their easier collection and faster engraftment. The optimal mobilization schedule for stem cell harvest is a matter of permanent research, since collecting the maximum dose of CD34 + cells is being proposed in order to facilitate subsequent manipulation and shorten granulocyte and platelet engraftment. Although chemotherapy plus growth factors has been reported repeatedly to result in collecting higher numbers of CD34 + cells than G-CSF alone, it has several disadvantages such as a longer mobilization period, chemotherapy toxicity and febrile neutropenia. Moreover, optimal timing of apheresis is not easily scheduled and this hinders optimal progenitor collection especially in patients referred from other regions.
In children, peripheral blood progenitor cells (PBPC) are progressively substituting bone marrow as a source of stem cells for hematopoietic transplantation due to their easier collection and faster engraftment. The optimal mobilization schedule for stem cell harvest is a matter of permanent research, since collecting the maximum dose of CD34 + cells is being proposed in order to facilitate subsequent manipulation and shorten granulocyte and platelet engraftment. Although chemotherapy plus growth factors has been reported repeatedly to result in collecting higher numbers of CD34 + cells than G-CSF alone, it has several disadvantages such as a longer mobilization period, chemotherapy toxicity and febrile neutropenia. Moreover, optimal timing of apheresis is not easily scheduled and this hinders optimal progenitor collection especially in patients referred from other regions.
In order to improve the progenitor cell collection in our patients, using only cytokines, we designed a new mobilization schedule based on previously reported findings. First, based on the dose-response effect found by Weaver et al 1 we increased the total dose of G-CSF administered to our patients for priming. Second, as other authors recommended, we divided this increased total dose of G-CSF to improve hematopoietic progenitor cell mobilization.
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Therefore, we have conducted a clinical study to evaluate this new mobilization regimen consisting of larger doses of G-CSF than previously used in our institution and with the total daily dose divided and administered every 12 h. This study was performed to analyze secondary effects during G-CSF mobilization and the proportion of patients that achieved the minimum and optimum CD34 + cell dose.
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Patients and methods
Fifty-five patients diagnosed with hematological malignancies and solid tumors, underwent PBPC collections by large volume leukapheresis (LVL) between January 1999 and July 2001 for autologous transplantation after their first mobilization with G-CSF (Filgrastim; Amgen, Thousand Oaks, CA, USA) at a dose of 12 g/kg BW subcutaneously twice daily for 4 days ( Table 1) . LVL were performed in the Pediatric Oncology Department using a COBE Spectra cell separator (COBE, Denver, CO, USA), via central venous catheter, mainly by femoral access (Arrow-Howes, Reading, PA, USA) with offset lumens as described elsewhere. 6 An attempt was made to use the same catheter for harvesting and transplantation. Leukapheresis was performed on the 5th day of mobilization. Parental consent was obtained before every procedure. Secondary effects related to mobilization were recorded prospectively (headache, abdominal pain, myalgia or bone pain, low-grade fever, and nausea or vomiting). Adverse effects of leukapheresis were evaluated retrospectively until December 1999 and prospectively recorded from January 2000 according to the Hemapheresis Committee of the American Association of Blood Banks questionnaire. 7 Each different course of chemotherapy the patient received before the apheresis was counted as a chemotherapy cycle in Table 1. CD34 + cell determination was performed as previously reported. 6 Two million CD34 + cells/kg body weight (BW) was established as the minimum CD34 + cell dose required, and 5 ϫ 10 6 CD34 + cells/kg BW was considered to be an optimum collection. 5 Collection efficiency (CE) was calculated according to the Ford et al formula, 8 and recruitment according to Torrabadella et al. 9 A software program (Statview 4.0; Abacus Concept, Berkeley, CA, USA) was used for statistical analysis. Correlations were determined using linear regression. The influence of variables that could affect the CD34 + cell count preapheresis and CD34
+ cell yield were examinated by univariate and multivariate analysis using a stepwise regression model. CD34
+ cell yield between patients younger and older than 7 years was also analyzed with a non-parametric test (Mann-Whitney U). Results were considered significant if the P value was Ͻ0.05.
Results
Toxicity secondary to G-CSF priming was observed in 13 patients (23%). Adverse events included mild bone pain and myalgia (9), low-grade fever (4) and headache (6) . None of these patients needed to reduce the dose or discontinue G-CSF due to side-effects. We have performed this priming schedule in 16 further patients who previously failed to achieved the target CD34 + cell dose with other regimens, with similar toxicities.
LVL characteristics are shown in Table 2 .
The median CD34 + cell number collected was 4.4 (0.4-35 ϫ 10 6 /kg BW), with 46 patients achieving the minimum dose (83.6%) and 27 patients the optimum dose (49.1%) ( Table 2) .
LVL were performed without serious adverse events. Nine patients suffered mild tachycardia and only two of them transient and reversible hypotension. Pain at the venipuncture site (4) and minor bleeding after removal of central venous catheters (3) were the other complications reported. No procedure needed to be interrupted as the result of any physical difficulty. Median platelet loss was 47% (12-81). It was related, as expected, to the volume/kg BW processed (r = 0.6; P = 0.0001). CD34 + cells in the collection (CD34 + cell/kg BW) were related to CD34 + cell counts in peripheral blood preapheresis (r = 0.8; P = 0.0001), and to age (r = 0.4; P = 0.002) ( Table 3 ). CD34
+ cell count in peripheral blood preapheresis and CD34
+ cell/kg BW were higher in those patients younger than 7 years old ( Table 2) . We could not find other variables related to the yield, including diagnosis, and prior chemotherapy or radiotherapy, probably due to the small number of patients in the study.
Discussion
We have performed this study in order to define a better priming regimen and to evaluate its toxicities, and we have achieved the target CD34
+ cell dose in a higher proportion of patients than with previous mobilization schedules without significant secondary effects during G-CSF treatment.
Our mobilization schedule initially consisted of G-CSF at a dose of 12 g/kg/day subcutaneously. 10 It allowed us to collect the target dose of 1 ϫ 10 6 CD34 + cells/kg BW in a single apheresis in 68% of our pediatric patients. 11 Processing larger blood volumes we achieved in a subsequent series the target CD34
+ cell dose in a single apheresis in 92.5% of our patients. 12 However, after early and long-term engraftment kinetic evaluation in our series, the minimum target CD34
+ cell dose was increased to 2 ϫ 10 6 CD34
+ cells/kg BW, and 5 ϫ 10 6 CD34 + cells/kg BW was considered an optimum number. 5 With this new minimum target CD34
+ cell dose a higher number of patients did not reach an acceptable yield. Therefore, we decided to study the combination of cytokines to optimize the mobilization comparing G-CSF+GM-CSF with G-CSF alone, and no differences in terms of progenitor yield and subsequent engraftment was observed. 13 We have finally evaluated in this study the yields when priming with larger and daily divided doses [1] [2] [3] [4] with the results described above. Some authors have published that priming with G-CSF at 20 g/kg per day did not improve the collection in children but, with the schedule described herein, we have increased not only the number of patients that only need one procedure to achieve the minimum target CD34
+ cell dose, but also the median number of CD34 + cells collected when compared with our own previous series. 13 No serious toxicities were found in this series during the mobilization period. A higher number of secondary effects are described in this study than previously reported in children with similar doses of G-CSF, 14 but lower than reported with similar or even lower doses of G-CSF in adult patients. 1, 4 Moreover, as mentioned above, none of these patients needed to reduce or discontinue G-CSF treatment due to side-effects. CD34 + cell collection was significantly higher in those patients younger than 7 years old in our series. It might be a bias, since in this group of patients central nervous system tumors are more frequent than in older children, and children with this diagnosis usually received fewer chemotherapy cycles (a variable well known to influence the yield) before mobilization. However this issue needs to be clarified in future studies with a larger number of patients.
In conclusion, this mobilization schedule based on high and daily divided dose of G-CSF (12 g/kg BW twice daily for 4 days) followed by LVL allows safe and efficient collection of the minimum target CD34 + cell dose (2 ϫ 10 6 /kg) in most pediatric patients by only one procedure. To improve the yield, especially in patients older than 7 years, higher doses of G-CSF may be studied in the future since pediatric patients seem to have fewer secondary effects related to this drug.
